![]() ![]() We are developing a diverse pipeline in a broad range of therapeutic areas of wholly owned and partnered programs. Based on our Target Vector Profile for a disease, we select customized capsids in non-human primates from an estimated over one billion vector capsid sequences in our 37 proprietary and diverse AAV vector libraries as of August 1, 2019. We use our platform to discover custom and proprietary AAVs designed for specific tissues and diseases, which we believe will allow us to overcome known limitations of conventional AAV vectors and potentially address a broad range of both rare and large market diseases. 12, 2021 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second quarter of 2021, and provided operational highlights. Our transformative discovery platform, Therapeutic Vector Evolution, enables our “disease first” approach to product discovery, design and development. Domokos Lauko Scientist I at 4D Molecular Therapeutics Berkeley, California, United States 123 followers 121 connections Join to view profile 4D Molecular Therepeutics University of. Premium Products Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens A+ Investor Full access to, Journal, and a. We are pioneering the development of precision gene therapies based on our proprietary AAV vectors. Using its Directed Vector Evolution platform, Emeryville, CAs, 4D Molecular Therapeutics says it can create a library of 100 million gene vectors and. Reviews from 4D Molecular Therapeutics employees about 4D Molecular Therapeutics culture, salaries, benefits, work-life balance, management, job security, and more. As of Thursday, June 22, 4D Molecular Therapeutics Inc’s FDMT share price has dipped by 4.73, which has investors questioning if this is right time to buy. We strive to become the most impactful company in the gene therapy industry. 4DMT is a leader in next-generation AAV gene therapy discovery through its proprietary therapeutic vector evolution platform that empowers us to invent optimized and proprietary AAV vectors, each specifically tailored for the treatment of a rare disease with a high unmet medical need. 4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights. It is expected to price during the week of December 7, 2020.We are 4DMT! Our mission is to boldly innovate to unlock the full potential of gene therapy for countless patients. It is developing a pipeline of gene therapy product candidates designed to treat. Goldman Sachs, BofA Securities and Evercore ISI are the joint bookrunners on the deal. 4D Molecular Therapeutics is a developer of precision gene therapies. It plans to list on the Nasdaq under the symbol FDMT. Emeryville, CA 4D Molecular Therapeutics, Inc. It has two additional candidates that it expects to file INDs for in the 2H21.ĤD Molecular Therapeutics was founded in 2013 and booked $17 million in collaboration and license revenue for the 12 months ended September 30, 2020. Its lead candidates include 4D-125, which is currently in a Phase 1/2 trial for X-linked retinitis pigmentosa with initial data expected in 2021 4D-110, which is currently in a Phase 1 trial for choroideremia with initial data expected in 2022 and 4D-310, which is currently in a Phase 1/2 trial for Fabry disease with initial data expected in 2021. The mission of 4D Molecular Therapeutics is to design and develop transformative gene therapy products using our proprietary. At the midpoint of the proposed range, 4D Molecular Therapeutics would command a fully diluted market value of $491 million.ĤD is developing product candidates using its targeted and evolved AAV vectors, initially focusing on ophthalmology, cardiology, and pulmonology. The Emeryville, CA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22. 4D Molecular Therapeutics designs, develops and commercializes transformative gene therapeutic products for serious unmet medical. 4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, announced terms for its IPO on Monday. ![]()
0 Comments
Leave a Reply. |